ClinicalTrials.gg
CompletedNCT02151149ABOUND 70+Updated Sep 24, 2018Results posted

Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly

A Phase 4 interventional study of nab-paclitaxel and Carboplatin in Non-Small Cell Lung Cancer, Carcinoma and Squamous Cell Carcinoma, sponsored by Celgene. Completed at 55 sites in United States. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2018-09-24.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 11 under way, 1 of them phase 3. Albumin-Bound Paclitaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
13th of 47
143 · median 64
Started
2014
with 2 others
Phase 4
2 of 47
none open now
Registered
17th of 47
by date
Lead sponsor
7 of 47
Celgene

Among the 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is one of 3 that started in 2014, is one of 2 in phase 4, and was the 17th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC

Read the detailed description

This is a Phase IV, randomized, open-label, multicenter study of continuous weekly versus weekly times three with one-week break nab-paclitaxel in combination with carboplatin as first-line treatment in elderly subjects (≥ 70 years old) with advanced non small cell lung cancer who have not received prior chemotherapy for their advanced disease and are not candidates for curative surgery or radiation therapy. The primary study endpoint is the percentage of subjects with either peripheral neuropathy or myelosuppression adverse events. Patients will continue treatment until they develop progressive disease, unacceptable side-effects or wish to withdraw from the study, according to local standard of care. Patients will have radiographic evaluations every 6 weeks while on treatment.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Carcinoma
  • Squamous Cell Carcinoma
  • Adenocarcinoma
  • Carcinoma, Large Cell
  • Lung Neoplasm

Keywords

  • NSCLC advanced non-small cell lung cancer squamous adenocarcinoma large cell carcinoma lung cancer elderly first line treatment abraxane carbo nab-paclitaxel
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: -

  • Inclusion Criteria: -

    1. Age ≥ 70 years at the time of signing the Form.
    2. Understand and voluntarily provide written informed consent prior to the conduct of any study related assessments/procedures.
    3. Able to adhere to the study visit schedule and other protocol requirements.
    4. or cytologically confirmed locally advanced or non small cell lung cancer who are not candidates for curative surgery or radiation therapy.
    5. No other current active requiring anticancer therapy.
    6. Radiographically documented per v 1.1
    7. No prior chemotherapy for the treatment of metastatic disease. chemotherapy is permitted providing that cytotoxic chemotherapy was completed 12 months prior to signing the informed consent form (ICF) and without disease recurrence. Participans with previously known epidermal growth factor receptor mutation or anaplastic lymphoma kinase gene translocation must have failed or had intolerance to one treatment with epidermal growth factor receptor tyrosine kinase inhibitor or anaplastic lymphoma kinase inhibitor therapy, respectively.
    8. ≥ 1500 cells/cubic millimetre.
    9. ≥ 100,000 cells/cubic millimetre.
    10. ≥ 9 grams/decilitre.
    11. /serum glutamic oxaloacetic transaminase/ alanine transaminase/serum glutamic pyruvic transaminase ≤ 2.5 × or ≤ 5.0 × upper limit of normal range if liver metastases.
    12. Total ≤ 1.5 millilitre/decilitre (unless there is a known history of Gilberts Syndrome).
    13. > 40 millilitre/minute calculated using Cockcroft-Gault equation (if renal impairment is suspected 24 hour urine collection for measurement is required).
    14. performance status 0 or 1.
    15. Females who (1) have undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have been naturally for at least 24 consecutive months (ie, has not had menses at any time during the preceding 24 consecutive months).
    16. Male subjects must: Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of while participating in the study, during dose interruptions and for 6 months following study drug discontinuation, even if he has undergone a successful vasectomy.

      Exclusion Criteria:

    1. Evidence of active , including (prior evidence of brain metastasis are permitted only if treated and stable and off therapy for ≥ 4 weeks prior to signing Informed consent form. Magnetic Resonance Imaging of the brain (or Computed Tomography scan w/contrast) is preferred for diagnosis.

      1. History of leptomeningeal disease. 3. Only evidence of disease is non measurable. 4. Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per v4.0).
      1. Participant has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting product, and/or from whom ≥ 30% of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
      1. Venous thromboembolism within 1 month prior to signing informed consent form.
      1. Current congestive heart failure ( Class II-IV). 8. History of the following within 6 months prior to first administration of a study drug: a myocardial infarction, severe/unstable angina pectoris,coronary/peripheral artery bypass graft, New York Heart Association Class III-IV heart failure, uncontrolled hypertension, cardiac dysrhythmia or clinically significant abnormality, cerebrovascular accident, , or seizure disorder.
      1. Participant has a known infection with or C, or history of infection, or participant is receiving or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications.
      1. Participant has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.

      11.History of interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or pulmonary pneumonitis.

      1. Treatment with any investigational product within 28 days prior to signing the informed consent form.
      1. History of allergy or hypersensitivity to nab-paclitaxel or carboplatin. 14. Currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices. 15. Any other clinically significant medical condition, psychiatric illness, and/or organ dysfunction that will interfere with the administration of the therapy according to this protocol or which, in the views of investigator, preclude combination chemotherapy.
      1. Participant has any other malignancy within 5 years prior to randomization. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer Tumor, Lymph Node, Metastatic (TNM stage of T1a or T1b). All treatment of which should have been completed 6 months prior to signing Informed consent form.
      1. Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study.
      1. Any medical condition that confounds the ability to interpret data from the study.
      1. Females who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months).
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Other
    Arm A: nab-Paclitaxel and Carboplatin (Every 21 days)

    nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg\*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle

    Drug: nab-paclitaxel · Drug: Carboplatin

  • Other
    Arm B: nab-Paclitaxel and Carboplatin (Every 28 days)

    nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg\*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break

    Drug: nab-paclitaxel · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade 3 Based on Local Laboratory Values

    Peripheral neuropathy (sensory or motor) assessment was done at screening, on Days 1, 8, 15 of every treatment cycle, at the End-of-Treatment visit and at the 28-day Follow-up Visit. Changes in neuropathy grade from baseline was reported as an AE as assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Myelosuppression in participants receiving chemotherapy may have manifested as neutropenia, thrombocytopenia, or anemia. Grade 3 neutropenia including an absolute neutropenia count (ANC) of 500 to 1,000 cells/mm\^3; anemia hemoglobain levels (Hgb) \<8.0 - 6.5 g/dL; \<4.9 - 4.0 mmol/L; \<80 - 65 g/L; transfusion indicated; and thrombocytopenia with platelet levels \<100,000 cells/mm\^3.

    Time frame: From the date of the first dose of investigational product (IP) until 28 days after the last dose of IP; up to data cut-off date of 20 November 2016; The median treatment duration for Arms A and B were 3.04 months and 5.17 months respectively.

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events During the Treatment Period

    Treatment-emergent adverse events (TEAEs) were defined as any AE or serious adverse event (SAE) that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP. Any SAE with an onset date more than 28 day after the last dose of IP that was assessed by the investigator as related to IP was considered a TEAE. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and based on the scale: Grade 1 = Mild - transient or mild discomfort; Grade 2 = Moderate - mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required; Grade 3 = Severe - marked limitation in activity, assistance usually required; medical intervention required, hospitalization is possible; Grade 4 = Life threatening - extreme limitation in activity, assistance required; medical intervention, hospitalization or hospice care probable; Grade 5 = death.

    Time frame: From the date of the first dose of IP until 28 days after the last dose of IP; up to a later data cut-off date of 14 July 2017; maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively.

  2. Percentage of Participants With at Least 1 Treatment Emergent Adverse Event With Action Taken as Study Drug Withdrawn

    The percentage of participants with at least 1 TEAE with action taken as studydrug withdrawn during the treatment period of the trial was assessed throughout the conduct of the study. Study drug withdrawn (treatment permanently discontinued) was attributed to the part in which the onset of the adverse event took place.

    Time frame: From the date of the first dose of IP until 28 days after the last dose of IP; up to a later data cut-off date of 14 July 2017 the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively

  3. Dose Intensity Per Week of Nab-Paclitaxel During the Entire Study

    Dose intensity was the cumulative dose divided by the dosing period in weeks.

    Time frame: From day 1 of study treatment to the end date of study treatment; up to data cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively

  4. Dose Intensity Per Week of Carboplatin During the Entire Study

    Dose intensity for carboplatin was the cumulative dose divided by the dosing period in weeks."

    Time frame: From day 1 of study treatment to the end date of study treatment; up to data cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively

  5. Percentage of Participants With Dose Reductions During the Entire Study

    A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities.

    Time frame: From the first dose of study treatment to discontinuation date of study treatment; up to date cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively

  6. Percentage of Participants With a Dose Delay During the Entire Study

    A dose delay occurred when the dose assigned at a visit was held compared to the previous visit. Dose delays were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities.

    Time frame: From the first dose of study treatment to discontinuation date of study treatment; up to date cut off date of 16 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively

  7. Kaplan Meier Estimate of Progression-Free Survival (PFS)

    Progression-free survival was defined as the time in months from day 1 of treatment to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. RECIST V1.1 criteria includes: - Complete Response (CR) is the disappearance of all target lesions; - Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions from baseline; - Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease (PD); - Progressive Disease is at least a 20% increase in the sum of diameters of target lesions from nadir

    Time frame: From first dose of IP to the date of disease progression; up to a later clinical cut-off date of 14 July 2017; for Arms A and B participants were followed for PFS for 31 months and 20 months respectively

  8. Kaplan Meier Estimate of Overall Survival (OS)

    Overall survival was defined as the time in months between day 1 of treatment and death from any cause). Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact.

    Time frame: From first dose of IP to the date of death due to any cause; up to a later clinical cut-off date of 14 July 2017; for Arms A and B participants were followed for OS for 31 months and 33 months respectively

  9. Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 Criteria

    Overall response rate (ORR) was defined as the percentage of participants who had radiologic CR or PR compared to baseline (radiographic evaluation on the day of or within 28 days prior to randomization) according to RECIST Version 1.1 criteria as determined by the investigator, which was confirmed by repeated radiologic assessment performed no less than 28 days after the criteria for response were first met and occurred between Day 1 of treatment and the start of subsequent anticancer therapy, death or study discontinuation. A complete response and partial response per RECIST V 1.0 criteria was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of diameters of target lesions from baseline.

    Time frame: From the first dose of IP to the date of documented first response; up to the data cut-off date of 14 July 2017; maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively.

07

Results

Posted Sep 24, 2018

Participant flow

This multicenter study was conducted in the United States and enrolled participants at a total of 41 sites.

Treatment Period
Participant flow — Treatment Period
MilestoneArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
Started7172
Treated population6870
Completed11
Not completed7071
Withdrew: Death23
Withdrew: Adverse event1714
Withdrew: Progressive disease2524
Withdrew: Symptomatic deterioration210
Withdrew: Withdrawal by subject1311
Withdrew: Miscellaneous87
Withdrew: Participants randomized but not treated32
Follow-Up Period
Participant flow — Follow-Up Period
MilestoneArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
Started5855
Completed1918
Not completed3937
Withdrew: Lost to follow-up23
Withdrew: Death3734

Outcome measures

PrimaryPercentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade 3 Based on Local Laboratory Values

Peripheral neuropathy (sensory or motor) assessment was done at screening, on Days 1, 8, 15 of every treatment cycle, at the End-of-Treatment visit and at the 28-day Follow-up Visit. Changes in neuropathy grade from baseline was reported as an AE as assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Myelosuppression in participants receiving chemotherapy may have manifested as neutropenia, thrombocytopenia, or anemia. Grade 3 neutropenia including an absolute neutropenia count (ANC) of 500 to 1,000 cells/mm\^3; anemia hemoglobain levels (Hgb) \<8.0 - 6.5 g/dL; \<4.9 - 4.0 mmol/L; \<80 - 65 g/L; transfusion indicated; and thrombocytopenia with platelet levels \<100,000 cells/mm\^3.

Time frame:
From the date of the first dose of investigational product (IP) until 28 days after the last dose of IP; up to data cut-off date of 20 November 2016; The median treatment duration for Arms A and B were 3.04 months and 5.17 months respectively.
Reported as:
Number · Percentage of Participants
Percentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade 3 Based on Local Laboratory Values
Percentage of ParticipantsArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
Percentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade 3 Based on Local Laboratory Values76.5 (64.6 to 85.9)77.1 (65.6 to 86.3)
Statistical analysis
  • Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) vs Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) · Cochran-Mantel-Haenszel · p = 0.9258 · Risk ratio (rr): 1.01 · 95% CI 0.84 to 1.21Based on stratification factors of ECOG PS at screening (0 vs. 1) and histology (squamous cell carcinoma vs. non-squamous cell carcinoma).
SecondaryNumber of Participants With Treatment Emergent Adverse Events During the Treatment Period

Treatment-emergent adverse events (TEAEs) were defined as any AE or serious adverse event (SAE) that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP. Any SAE with an onset date more than 28 day after the last dose of IP that was assessed by the investigator as related to IP was considered a TEAE. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and based on the scale: Grade 1 = Mild - transient or mild discomfort; Grade 2 = Moderate - mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required; Grade 3 = Severe - marked limitation in activity, assistance usually required; medical intervention required, hospitalization is possible; Grade 4 = Life threatening - extreme limitation in activity, assistance required; medical intervention, hospitalization or hospice care probable; Grade 5 = death.

Time frame:
From the date of the first dose of IP until 28 days after the last dose of IP; up to a later data cut-off date of 14 July 2017; maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events During the Treatment Period
ParticipantsArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
Treatment Emergent Adverse Event6869
Serious Treatment Emergent Adverse Event2332
Grade 3 or 4 Treatment Emergent Adverse Event6059
Grade 3 or Higher Treatment Emergent Adverse Event6061
Treatment Related TEAE6566
Treatment-Related Serious TEAE1212
TEAE with Action to Reduce or Interrupt IP Dose6054
Treatment-Related Action to Reduce/Interrupt IP5651
TEAE with Action Taken as Study Drug Withdrawn1714
Treatment-related TEAE with Action to Halt IP1313
TEAE with Fatal Outcome13
Treatment-related TEAE with Fatal Outcome00
SecondaryPercentage of Participants With at Least 1 Treatment Emergent Adverse Event With Action Taken as Study Drug Withdrawn

The percentage of participants with at least 1 TEAE with action taken as studydrug withdrawn during the treatment period of the trial was assessed throughout the conduct of the study. Study drug withdrawn (treatment permanently discontinued) was attributed to the part in which the onset of the adverse event took place.

Time frame:
From the date of the first dose of IP until 28 days after the last dose of IP; up to a later data cut-off date of 14 July 2017 the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least 1 Treatment Emergent Adverse Event With Action Taken as Study Drug Withdrawn
Percentage of ParticipantsArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
Percentage of Participants With at Least 1 Treatment Emergent Adverse Event With Action Taken as Study Drug Withdrawn25.020.0
SecondaryDose Intensity Per Week of Nab-Paclitaxel During the Entire Study

Dose intensity was the cumulative dose divided by the dosing period in weeks.

Time frame:
From day 1 of study treatment to the end date of study treatment; up to data cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively
Reported as:
Mean · mg/m^2/week
Dose Intensity Per Week of Nab-Paclitaxel During the Entire Study
mg/m^2/weekArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
Dose Intensity Per Week of Nab-Paclitaxel During the Entire Study64.07 ± 17.37456.57 ± 16.645
SecondaryDose Intensity Per Week of Carboplatin During the Entire Study

Dose intensity for carboplatin was the cumulative dose divided by the dosing period in weeks."

Time frame:
From day 1 of study treatment to the end date of study treatment; up to data cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively
Reported as:
Mean · mg*min/mL/week
Dose Intensity Per Week of Carboplatin During the Entire Study
mg*min/mL/weekArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
Dose Intensity Per Week of Carboplatin During the Entire Study1.51 ± 0.3841.33 ± 0.671
SecondaryPercentage of Participants With Dose Reductions During the Entire Study

A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities.

Time frame:
From the first dose of study treatment to discontinuation date of study treatment; up to date cut off date of 20 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively
Reported as:
Number · Percentage of Participants
Percentage of Participants With Dose Reductions During the Entire Study
Percentage of ParticipantsArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
nab-Paclitaxel64.758.6
Carboplatin57.458.6
SecondaryPercentage of Participants With a Dose Delay During the Entire Study

A dose delay occurred when the dose assigned at a visit was held compared to the previous visit. Dose delays were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities.

Time frame:
From the first dose of study treatment to discontinuation date of study treatment; up to date cut off date of 16 November 2016; the maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Dose Delay During the Entire Study
Percentage of ParticipantsArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
nab-Paclitaxel58.848.6
Carboplatin52.944.3
SecondaryKaplan Meier Estimate of Progression-Free Survival (PFS)

Progression-free survival was defined as the time in months from day 1 of treatment to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. RECIST V1.1 criteria includes: - Complete Response (CR) is the disappearance of all target lesions; - Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions from baseline; - Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease (PD); - Progressive Disease is at least a 20% increase in the sum of diameters of target lesions from nadir

Time frame:
From first dose of IP to the date of disease progression; up to a later clinical cut-off date of 14 July 2017; for Arms A and B participants were followed for PFS for 31 months and 20 months respectively
Reported as:
Median · months
Kaplan Meier Estimate of Progression-Free Survival (PFS)
monthsArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
Kaplan Meier Estimate of Progression-Free Survival (PFS)3.88 (3.02 to 6.24)7.20 (5.85 to 11.53)
Statistical analysis
  • Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) vs Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) · Stratified Log Rank · p = 0.0036 · Hazard ratio (hr): 0.52 · 95% CI 0.33 to 0.81Based on stratification factors of ECOG PS at screening (0 vs. 1) and histology (squamous cell carcinoma vs. non-squamous cell carcinoma).
SecondaryKaplan Meier Estimate of Overall Survival (OS)

Overall survival was defined as the time in months between day 1 of treatment and death from any cause). Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact.

Time frame:
From first dose of IP to the date of death due to any cause; up to a later clinical cut-off date of 14 July 2017; for Arms A and B participants were followed for OS for 31 months and 33 months respectively
Reported as:
Median · months
Kaplan Meier Estimate of Overall Survival (OS)
monthsArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
Kaplan Meier Estimate of Overall Survival (OS)14.52 (9.46 to 17.28)14.98 (12.09 to 18.73)
Statistical analysis
  • Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) vs Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) · Stratified log-rank test · p = 0.3537 · Hazard ratio (hr): 0.82 · 95% CI 0.54 to 1.25Based on stratification factors of ECOG PS at screening (0 vs. 1) and histology (squamous cell carcinoma vs. non-squamous cell carcinoma).
SecondaryPercentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 Criteria

Overall response rate (ORR) was defined as the percentage of participants who had radiologic CR or PR compared to baseline (radiographic evaluation on the day of or within 28 days prior to randomization) according to RECIST Version 1.1 criteria as determined by the investigator, which was confirmed by repeated radiologic assessment performed no less than 28 days after the criteria for response were first met and occurred between Day 1 of treatment and the start of subsequent anticancer therapy, death or study discontinuation. A complete response and partial response per RECIST V 1.0 criteria was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of diameters of target lesions from baseline.

Time frame:
From the first dose of IP to the date of documented first response; up to the data cut-off date of 14 July 2017; maximum treatment duration for Arms A and B was 16.6 months and 20.1 months respectively.
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 Criteria
Percentage of participantsArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 Criteria26.8 (16.9 to 38.6)41.7 (30.2 to 53.9)
Statistical analysis
  • Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce) vs Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle) · Cochran-Mantel-Haenszel · p = 0.0597 · Risk ratio (rr): 1.56 · 95% CI 0.971 to 2.511Based on stratification factors of ECOG PS at screening (0 vs. 1) and histology (squamous cell carcinoma vs. non-squamous cell carcinoma)..

Adverse events

Collected over TEAEs are reported up to 37 months; from Day 1 of IP until 28 days after the last dose of IP and those SAEs made known to the Investigator at any time thereafter being suspected of being related to IP; up data cut-off date of 14 July 2017.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)45/71 (63.4%)23/68 (33.8%)68/68 (100%)
Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)46/72 (63.9%)32/70 (45.7%)69/70 (98.6%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
NeutropeniaBlood and lymphatic system disorders6/683/70
DyspnoeaRespiratory, thoracic and mediastinal disorders3/686/70
PneumoniaInfections and infestations2/685/70
DiarrhoeaGastrointestinal disorders4/682/70
Atrial fibrillationCardiac disorders1/683/70
Febrile neutropeniaBlood and lymphatic system disorders2/681/70
VomitingGastrointestinal disorders2/682/70
DehydrationMetabolism and nutrition disorders2/682/70
Muscular weaknessMusculoskeletal and connective tissue disorders2/680/70
SyncopeNervous system disorders2/682/70
Most frequent other events
Showing 10 of 62
Most frequent other events
EventArm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)
FatigueGeneral disorders46/6837/70
AnaemiaBlood and lymphatic system disorders45/6839/70
Peripheral sensory neuropathyNervous system disorders40/6830/70
NauseaGastrointestinal disorders32/6837/70
NeutropeniaBlood and lymphatic system disorders35/6832/70
ThrombocytopeniaBlood and lymphatic system disorders30/6819/70
DiarrhoeaGastrointestinal disorders29/6826/70
AlopeciaSkin and subcutaneous tissue disorders27/6829/70
Decreased appetiteMetabolism and nutrition disorders22/6826/70
ConstipationGastrointestinal disorders25/6820/70

Baseline characteristics

Intent to Treat Population included all randomized participants regardless of whether the participant received any study drug or had any efficacy assessments performed.

Age, Continuous
Age, Continuous(years)Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)Total
Mean76.7 ± 4.1376.4 ± 5.1876.6 ± 4.67
Age, Customized
Age, Customized(Participants)Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)Total
70-74 years203353
75-79 years301848
80-84 years191736
85-89 years224
≥ 90 years022
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)Total
Female303262
Male414081
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)Total
American Indian or Alaska Native011
Asian033
Black or African American3710
Native Hawaiian or Other Pacific Islander011
White6457121
Other112
Data Missing325
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)(Participants)Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)Total
0 = Fully Active212041
1 = Restricted in Physical Activity; Ambulatory5052102
2 = Ambulatory and Capable of All Self-care000
3 = Capable of Only Limited Self-care000
4 = Completely Disabled.000
Confirmed Histology
Confirmed Histology(Participants)Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)Total
Squamous Cell Carcinoma272855
Non-Squamous Cell Carcinoma444488
Stage of Disease at Enrollment
Stage of Disease at Enrollment(Participants)Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)Total
IIIa459
IIIb6814
IV6059119
Data Missing101
Number of Prior Systemic Anticancer Therapies for Non-Small Cell Lung Cancer (NSCLC)
Number of Prior Systemic Anticancer Therapies for Non-Small Cell Lung Cancer (NSCLC)(Therapies)Arm A: Nab-Paclitaxel and Carboplatin (21-day Treatment Cylce)Arm B: Nab-Paclitaxel and Carboplatin (28-day Treatment Cycle)Total
Median2.0 (1.0 to 2.0)2.0 (2.0 to 4.0)2.0 (1.0 to 4.0)

2 further baseline measures are reported on the registry.

08

Study locations

55 sites
  • Arizona Clinical Research Center
    Tucson, Arizona 85715, United States
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • Saint Jude Heritage Medical Center
    Fullerton, California 92835, United States
  • Global Cancer Research Institute (GCRI), Inc.
    Gilroy, California 95020, United States
  • Ventura County Hematology-Oncology Specialists
    Oxnard, California 93030, United States
  • Central Coast Medical Oncology Corporation
    Santa Maria, California 93454, United States
  • University of California Los Angeles
    Santa Monica, California 90404, United States
  • Rocky Mountain Cancer Centers, LLP
    Denver, Colorado 80218, United States
  • St Mary's Hospital and Regional Medical Center
    Grand Junction, Colorado 81501, United States
  • Lynn Cancer Institute
    Boca Raton, Florida 33486, United States
  • Baptist Cancer Inst
    Jacksonville, Florida 32207, United States
  • Ocala Oncology Center
    Ocala, Florida 34471, United States
  • Florida Hospital Cancer Institute
    Orlando, Florida 32804, United States
  • Northshore University Healthsystem Research Institute
    Evanston, Illinois 60201, United States
  • Oncology Specialists, S.C.
    Niles, Illinois 60714, United States
  • Franciscan St. Francis Health
    Indianapolis, Indiana 46237, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Western Kentucky Hematology and Oncology Group
    Paducah, Kentucky 42003, United States
  • West Jeffersion Medical Center
    Marrero, Louisiana 70072, United States
  • Ochsner Medical Institutions
    New Orleans, Louisiana 70123, United States
  • Medstar Health Research Institute
    Baltimore, Maryland 21237, United States
  • Reliant Medical Group
    Worcester, Massachusetts 01608, United States
  • Henry Ford Health System
    Detroit, Michigan 48202-268, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Center for Cancer and Hematologic Disease
    Cherry Hill, New Jersey 08003, United States
  • Regional Cancer Care Associates LLC
    East Brunswick, New Jersey 08816, United States
  • Saint Barnabas Medical Center
    Livingston, New Jersey 07039, United States
  • Carol G Simon Cancer Center
    Morristown, New Jersey 07962, United States
  • Somerset Hematology-Oncology Associates
    Somerville, New Jersey 08876, United States
  • Regional Cancer Care Associates LLC- Sparta division
    Sparta, New Jersey 07871, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Brookdale University Hospital and Medical Center
    Brooklyn, New York 11212, United States
  • Broome Oncology, LLC
    Johnson City, New York 13790, United States
  • Clinical Research Alliance
    Lake Success, New York 11042, United States
  • SUNY Upstate Medical University Medicine Oncology
    Syracuse, New York 13215, United States
  • Lineberger Cancer Center
    Chapel Hill, North Carolina 27599, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Forsyth Memorial Hospital, Inc.
    Winston-Salem, North Carolina 27103, United States
  • St Elizabeth Hospital
    Youngstown, Ohio 44501, United States
  • Cancer Centres of Southwest Okahoma Research
    Lawton, Oklahoma 73505, United States
  • Good Samaritan Hospital Corvalis
    Corvallis, Oregon 97330, United States
  • Oregon Health and Science University
    Portland, Oregon 97210, United States
  • Penn State Milton S Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Medical College
    Philadelphia, Pennsylvania 19107, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Texas Oncology, P.A.-Amarillo
    Amarillo, Texas 79106, United States
  • Baylor University Medical Center at Dallas
    Dallas, Texas 75246, United States
  • UTMB Galveston
    Galveston, Texas 77555-0565, United States
  • Texas Oncology, PA - Longview
    Longview, Texas 75601, United States
  • Virginia Mason Cancer Center
    Seattle, Washington 98101, United States
  • Northwest Cancer Specialists, P.C.
    Vancouver, Washington 98684, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Jul 2017, 37 months.

Results were first posted in Sep 2018, 1 year 2 months after primary completion.

Of 43 phase 4 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2014
First posted
May 30, 2014
StartActual
Jun 9, 2014
Primary completionActual
Jul 14, 2017
CompletionActual
Jul 14, 2017
Results first posted
Sep 24, 2018
Last update
Sep 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02151149
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
May 30, 2014
Start date
Jun 9, 2014
Primary completion
Jul 14, 2017
Completion
Jul 14, 2017
Results posted
Sep 24, 2018
Last update
Sep 24, 2018

Study contacts

Teng Jin Ong
study director · Celgene

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albumin-Bound Paclitaxel · Carboplatin

Start the discussion